On September 24, 2019 Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics, reported that it has achieved a fifth milestone in its collaboration with Takeda Pharmaceutical Company Limited (Takeda) (Press release, Crescendo Biologics, SEP 24, 2019, View Source [SID1234539730]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the global, strategic, multi-target collaboration and license agreement with Takeda that was announced in October 2016, Crescendo’s proprietary transgenic platform and engineering expertise is used to identify and configure Humabody-based therapeutics against certain targets selected by Takeda.

Under the terms of the agreement, Crescendo has successfully delivered three novel oncology-targeted Humabody lead molecules. Takeda has taken exclusive licenses to both of the first two programmes in this highly productive collaboration.

Theodora Harold, CEO of Crescendo Biologics, commented:

"Reaching this fifth technical milestone marks our continued progress towards our joint goal with Takeda of creating the next generation of differentiated cancer therapies and provides strong validation of the work being done at Crescendo."